Priority 2 from the Juvenile Idiopathic Arthritis (Netherlands) PSP
| UNCERTAINTY: What is the best treatment plan for each individual patient? (e.g. start a biological directly, which one, what to do when the first one does not work, and how can medication best be tapered off?) (JLA PSP Priority 2) | |
|---|---|
| Overall ranking | 2 |
| JLA question ID | 0094/2 |
| Explanatory note | This question is about precision medicine, and asks what treatment is effective for which patient. Importantly, it also asks about tapering off medication when the disease is in remission. |
| Evidence |
Systematic review - Davies et al. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes. A systematic review. Semin Arthritis Rheum 2017;46:584-593. Systematic review-based + expert panel - Ringold et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis and enthesitis. Arthritis Rheumatol 2019;71:846. |
| Health Research Classification System category | Inflammatory and immune system |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | See data spreadsheet on JLA website |
| Submitted by | See data spreadsheet on JLA website |
| PSP information | |
|---|---|
| PSP unique ID | 0094 |
| PSP name | Juvenile Idiopathic Arthritis (Netherlands) |
| Total number of uncertainties identified by this PSP. | 53 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 7 February 2020 |